Filtered By:
Drug: Beta-Blockers

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 494 results found since Jan 2013.

Is This Primary Exertional Headache?
Discussion Commonly occurring primary headaches include tension, cluster and migraine headaches. “Other primary headaches” are often situational. Patients can have more than 1 type of these “other” headaches along with more common headaches. Other primary headaches as a group tend to be self-limited with long remission periods. Some other primary headaches include: Thunderclap headache Explosive sudden onset with maximum intensity in less 1 minute and resolution within 5 minutes usually 43/100,000 persons in adults Primary or secondary Secondary causes include intracranial hemorrhage, stroke, thro...
Source: PediatricEducation.org - November 21, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Association of beta-blocker therapy at discharge with clinical outcomes in patients without heart failure or left ventricular systolic dysfunction after acute coronary syndrome: An updated systematic review and meta-analysis
CONCLUSIONS: In patients without heart failure or left ventricular systolic dysfunction after ACS in the contemporary PCI era, beta-blocker therapy may still be beneficial due to a potential reduced risk of all-cause death.PMID:36376209 | DOI:10.1016/j.acvd.2022.09.004
Source: Archives of Cardiovascular Diseases - November 14, 2022 Category: Cardiology Authors: Meng-Jin Hu Xiao-Ning Wang Jiang-Shan Tan Yue-Jin Yang Source Type: research

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news

Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis
ConclusionCurrent clinical evidence supports the effectiveness of pharmacological intervention with beta-blockers, amiodarone, magnesium sulfate, or calcium-channel blockers to reduce the incidence of POAF after lung surgery in patients with lung cancer. In the absence of contraindications, prophylaxis with beta-blockers seems to be the most effective of the treatments studied.
Source: European Journal of Clinical Pharmacology - October 12, 2022 Category: Drugs & Pharmacology Source Type: research